^
Association details:
| Biomarker: | LILRB4 overexpression |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | IO-202 (ILT-3 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A FIRST-IN-HUMAN PHASE 1 STUDY OF IO-202 (ANTI-LILRB4 MAB) IN ACUTE MYELOID LEUKEMIA (AML) WITH MONOCYTIC DIFFERENTIATION AND CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) PATIENTS
Published date:
05/11/2023
Excerpt:
In monotherapy, 1 CMML patient demonstrated Clinical Benefit for more than 1 year, and 1 AML patient achieved PR. In combination therapy, 1 AML patient with high LILRB4 expression who was refractory to azacitidine and venetoclax based combination therapy achieved CR, ongoing at 7+ months.
